Medical College of Wisconsin
CTSIResearch InformaticsREDCap

First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Tech Innov Patient Support Radiat Oncol 2022 Jun;22:50-54

Date

05/20/2022

Pubmed ID

35586786

Pubmed Central ID

PMC9108982

DOI

10.1016/j.tipsro.2022.04.005

Scopus ID

2-s2.0-85129945098 (requires institutional sign-in at Scopus site)   15 Citations

Abstract

The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.

Author List

Janssen TM, Aitken K, Alongi F, Barry A, Bernchou U, Boeke S, Hall WA, Hosni A, Kroon PS, Nachbar M, Saeed H, Jürgenliemk-Schulz IM, Schytte T, Verkooijen HM, Nowee ME, tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium

Author

William Adrian Hall MD Chair, Professor in the Radiation Oncology department at Medical College of Wisconsin